Key Points
- Arani Bose sold 7,500 shares on Nov. 25 at an average price of $300.19 for about $2.25M, reducing his stake to 275,261 shares (a 2.65% decrease); he had also sold 7,500 shares on Nov. 21 at $290.56.
- Penumbra beat Q expectations with $0.97 EPS vs. $0.90 expected and revenue of $354.69M (up 17.8% YoY), while the stock carries a market cap of $11.59B and a P/E of about 78.7.
- Analysts rate the stock a consensus "Moderate Buy" with an average target of $305.69, and institutional investors own roughly 88.9% of the company.
Penumbra, Inc. (NYSE:PEN - Get Free Report) EVP Johanna Roberts sold 1,800 shares of the company's stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $300.06, for a total transaction of $540,108.00. Following the completion of the transaction, the executive vice president owned 64,736 shares in the company, valued at approximately $19,424,684.16. This represents a 2.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Johanna Roberts also recently made the following trade(s):
- On Monday, November 10th, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $266.98, for a total transaction of $160,188.00.
- On Wednesday, October 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $249.70, for a total transaction of $149,820.00.
- On Tuesday, September 2nd, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $270.58, for a total transaction of $162,348.00.
Penumbra Trading Down 0.9%
Shares of PEN stock opened at $295.96 on Thursday. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $310.00. The company has a market capitalization of $11.59 billion, a PE ratio of 78.71, a price-to-earnings-growth ratio of 2.10 and a beta of 0.51. The firm has a 50 day moving average price of $258.75 and a two-hundred day moving average price of $257.67. The company has a quick ratio of 4.04, a current ratio of 6.75 and a debt-to-equity ratio of 0.02.
Penumbra (NYSE:PEN - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.07. The company had revenue of $354.69 million for the quarter, compared to analyst estimates of $340.77 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The firm's quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.85 earnings per share. Penumbra has set its FY 2025 guidance at EPS. As a group, analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. BTIG Research reissued a "buy" rating and issued a $320.00 target price on shares of Penumbra in a research report on Monday, October 27th. Royal Bank Of Canada cut their price objective on shares of Penumbra from $330.00 to $325.00 and set an "outperform" rating for the company in a report on Wednesday, July 30th. Wells Fargo & Company began coverage on shares of Penumbra in a report on Tuesday, November 18th. They set an "underweight" rating on the stock. JPMorgan Chase & Co. lifted their price target on shares of Penumbra from $265.00 to $275.00 and gave the company a "neutral" rating in a research report on Thursday, November 6th. Finally, Robert W. Baird increased their price target on Penumbra from $283.00 to $285.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $305.69.
Get Our Latest Stock Report on Penumbra
Institutional Investors Weigh In On Penumbra
Several institutional investors and hedge funds have recently added to or reduced their stakes in PEN. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Penumbra in the 1st quarter valued at $2,148,000. Cetera Investment Advisers lifted its position in shares of Penumbra by 56.9% during the 1st quarter. Cetera Investment Advisers now owns 2,757 shares of the company's stock worth $737,000 after buying an additional 1,000 shares during the last quarter. LPL Financial LLC boosted its stake in Penumbra by 167.8% in the first quarter. LPL Financial LLC now owns 25,408 shares of the company's stock valued at $6,794,000 after buying an additional 15,922 shares in the last quarter. Meeder Asset Management Inc. boosted its stake in Penumbra by 1,966.7% in the first quarter. Meeder Asset Management Inc. now owns 372 shares of the company's stock valued at $99,000 after buying an additional 354 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in Penumbra in the first quarter valued at about $173,000. 88.88% of the stock is currently owned by institutional investors.
About Penumbra
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
